INI-1 Immunohistochemistry at Test Zone Diagnostic Center

INI-1 Immunohistochemistry at Test Zone Diagnostic Center

The INI-1 Immunohistochemistry test at Test Zone Diagnostic Center in Lahore, Pakistan, is a highly specialized, state-of-the-art diagnostic pathology investigation. INI-1, also known as SMARCB1, SNF5, or BAF47, is a critical tumor suppressor protein encoded by the SMARCB1 gene located on the long arm of chromosome 22 (22q11.2). This protein is an essential, core subunit of the adenosine triphosphate (ATP)-dependent SWI/SNF chromatin-remodeling complex, which plays a pivotal role in eukaryotic gene expression, cell cycle regulation, lineage specification, and maintaining genomic stability. Under normal physiological conditions, the INI-1 protein is ubiquitously and constitutively expressed in the nuclei of virtually all human cells, including epithelial, mesenchymal, hematolymphoid, and neuroectodermal lineages. Consequently, immunohistochemical staining for INI-1 in normal tissues reveals strong, diffuse nuclear positivity. However, biallelic inactivating mutations, deletions, or epigenetic silencing of the SMARCB1 gene lead to a complete loss of the functional INI-1 protein. This loss of expression is a highly specific diagnostic hallmark of several aggressive, poorly differentiated, or epithelioid neoplasms. The INI-1 Immunohistochemistry test at Test Zone Diagnostic Center is a premier diagnostic tool utilized by oncologists, neurosurgeons, and pathologists to definitively identify these rare malignancies, differentiate them from morphologically similar mimics, and guide targeted therapeutic strategies. By utilizing highly specific monoclonal antibodies, our expert pathologists can visualize the presence or absence of this nuclear protein under a light microscope, providing critical diagnostic clarity that is essential for patient management and prognostic stratification.

Clinical Procedure: What to Expect

Patient Preparation

The INI-1 Immunohistochemistry test is an in vitro diagnostic assay performed on tissue specimens that have already been obtained through surgical procedures. Therefore, there is no direct physical preparation required for the patient on the day of the immunohistochemical staining itself. However, the initial acquisition of the tissue specimen—whether via fine-needle aspiration, core needle biopsy, incisional biopsy, or complete surgical resection—requires specific patient preparation. Patients undergoing surgical biopsy under local or general anesthesia must follow pre-operative guidelines, which typically include fasting (nil per os) for six to eight hours prior to the procedure, temporarily discontinuing anticoagulant or antiplatelet medications (such as aspirin, clopidogrel, or warfarin) under medical supervision to minimize bleeding risks, and arranging for post-procedure transportation. Once the biopsy is performed, the tissue specimen must be immediately placed in 10% neutral buffered formalin for optimal fixation (typically between 6 and 72 hours) to preserve cellular morphology and protein antigenicity. The formalin-fixed, paraffin-embedded (FFPE) tissue block or unstained tissue slides (usually cut at 4-micron thickness on charged slides) must then be submitted to the histopathology department at Test Zone Diagnostic Center along with a detailed clinical history and previous pathology reports.

During the Procedure

The laboratory phase of the INI-1 Immunohistochemistry test at Test Zone Diagnostic Center involves a highly standardized, multi-step protocol executed by skilled histotechnologists. First, the paraffin-embedded tissue sections are mounted on positively charged glass slides and baked to ensure tissue adherence. The slides undergo deparaffinization using xylene and are subsequently rehydrated through a series of descending grades of alcohol to water. To expose the target epitopes that may have been masked during formalin fixation, the tissue sections are subjected to Heat-Induced Epitope Retrieval (HIER) using a high-pH or low-pH buffer solution in a specialized pressure cooker or water bath. After cooling, endogenous peroxidase activity is blocked using hydrogen peroxide to prevent non-specific background staining. The tissue is then incubated with a highly specific primary monoclonal antibody directed against the C-terminus of the INI-1 (SMARCB1) protein. Following primary antibody incubation and thorough washing, a polymer-based secondary detection system conjugated with horseradish peroxidase (HRP) is applied. The visual signal is developed using 3,3′-diaminobenzidine (DAB) chromogen, which produces a crisp, brown precipitate in the nuclei where the INI-1 protein is retained. The slides are counterstained with hematoxylin to visualize cellular morphology, dehydrated, cleared, and coverslipped. A consultant pathologist then evaluates the slides under a high-resolution light microscope, assessing both the tumor cells and internal positive controls (such as endothelial cells, fibroblasts, or inflammatory cells) to ensure assay validity.

When is a INI-1 Immunohistochemistry Performed?

Suspected Atypical Teratoid/Rhabdoid Tumor (ATRT)

Atypical Teratoid/Rhabdoid Tumor (ATRT) is an extremely aggressive, highly malignant tumor of the central nervous system that primarily affects infants and young children. Patients often present with rapidly progressive neurological symptoms, including persistent vomiting, morning headaches, macrocephaly, lethargy, irritability, and cranial nerve palsies due to increased intracranial pressure. Under the microscope, ATRT can closely mimic other embryonal tumors, such as medulloblastoma, pineoblastoma, or primitive neuroectodermal tumors. Because the prognosis and treatment protocols for ATRT differ significantly from these other neoplasms, clinicians request INI-1 Immunohistochemistry to confirm the diagnosis. A complete loss of nuclear INI-1 expression in the tumor cells, with retained expression in the surrounding non-neoplastic stromal and vascular cells, is diagnostic of ATRT, enabling neuro-oncologists to initiate aggressive, tumor-specific therapeutic regimens immediately.

Evaluation of Suspected Epithelioid Sarcoma

Epithelioid sarcoma is a rare, slow-growing, but highly malignant soft tissue sarcoma that typically arises in the distal extremities (classic type) or proximal/axial regions (proximal type) of young adults. Clinically, it often presents as a firm, painless subcutaneous nodule or ulcerating lesion that can be mistaken for a benign inflammatory process, chronic ulcer, or other epithelioid malignancies like squamous cell carcinoma, melanoma, or epithelioid angiosarcoma. Pathologists utilize INI-1 Immunohistochemistry as a critical diagnostic marker because approximately 90% of epithelioid sarcomas exhibit a characteristic loss of INI-1 expression due to SMARCB1 gene inactivation. Demonstrating this loss helps differentiate epithelioid sarcoma from its morphological mimics, ensuring that patients receive appropriate wide local excision, regional lymph node evaluation, and systemic therapies.

Diagnosis of Renal Medullary Carcinoma and Malignant Rhabdoid Tumors of the Kidney

Malignant rhabdoid tumors of the kidney (MRTK) are highly lethal renal neoplasms occurring almost exclusively in infants, presenting with hematuria, a palpable abdominal mass, and fever. Similarly, renal medullary carcinoma (RMC) is an aggressive renal epithelial neoplasm that predominantly affects young patients with sickle cell trait or disease. Both MRTK and RMC are characterized by the loss of SMARCB1/INI-1 expression. Clinicians order INI-1 IHC on renal biopsy specimens to distinguish these highly aggressive tumors from other pediatric and adult renal masses, such as Wilms tumor, clear cell sarcoma of the kidney, or conventional renal cell carcinoma, which retain normal INI-1 expression. This distinction is vital, as rhabdoid and medullary carcinomas require highly specialized, intensive chemotherapy protocols.

Differential Diagnosis of Poorly Differentiated and Epithelioid Neoplasms

In diagnostic pathology, tumors with epithelioid morphology or poorly differentiated features present a significant diagnostic challenge. These can include poorly differentiated chordomas, epithelioid malignant peripheral nerve sheath tumors (EMPNST), and some forms of synovial sarcoma. Pathologists routinely incorporate INI-1 into a comprehensive immunohistochemical panel to narrow down the differential diagnosis. For instance, poorly differentiated chordomas of the skull base and spine show a loss of INI-1, whereas classic chordomas retain it. Similarly, EMPNSTs frequently show a loss of INI-1, which helps differentiate them from classic schwannomas or conventional malignant peripheral nerve sheath tumors.

Investigating Schwannomatosis and Familial Tumor Syndromes

Schwannomatosis is a rare genetic disorder characterized by the development of multiple non-intradermal schwannomas throughout the body, in the absence of bilateral vestibular schwannomas (which would indicate Neurofibromatosis Type 2). Germline mutations in the SMARCB1/INI-1 gene are implicated in a subset of familial and sporadic schwannomatosis cases. Pathologists perform INI-1 Immunohistochemistry on resected schwannomas to evaluate for a characteristic mosaic pattern of INI-1 loss (where some tumor cells show loss of expression while others retain it). This finding, combined with clinical criteria and genetic testing, helps confirm a diagnosis of schwannomatosis, allowing for appropriate familial screening, genetic counseling, and long-term surveillance.

What Does a INI-1 Immunohistochemistry Detect?

The INI-1 Immunohistochemistry test is designed to detect the presence or absence of the INI-1 (SMARCB1) protein within the nuclei of cells in a tissue sample. The following are the clinically appropriate findings and interpretations associated with this test:

• Complete loss of nuclear INI-1 expression in atypical teratoid/rhabdoid tumor (ATRT) cells.
• Retained nuclear INI-1 expression in medulloblastoma cells (ruling out ATRT).
• Complete loss of nuclear INI-1 expression in epithelioid sarcoma cells.
• Retained nuclear INI-1 expression in classic synovial sarcoma cells.
• Complete loss of nuclear INI-1 expression in malignant rhabdoid tumors of the kidney.
• Retained nuclear INI-1 expression in Wilms tumor cells.
• Complete loss of nuclear INI-1 expression in renal medullary carcinoma.
• Retained nuclear INI-1 expression in oncocytoma and chromophobe renal cell carcinoma.
• Complete loss of nuclear INI-1 expression in poorly differentiated chordoma of the skull base.
• Retained nuclear INI-1 expression in classic chordoma.
• Complete loss of nuclear INI-1 expression in epithelioid malignant peripheral nerve sheath tumors (EMPNST).
• Retained nuclear INI-1 expression in classic malignant peripheral nerve sheath tumors (MPNST).
• Mosaic pattern of nuclear INI-1 expression in schwannomas associated with schwannomatosis.
• Retained diffuse nuclear INI-1 expression in normal central nervous system parenchyma.
• Retained nuclear INI-1 expression in tumor-infiltrating lymphocytes (acting as an internal positive control).
• Retained nuclear INI-1 expression in vascular endothelial cells within the tumor tissue (internal positive control).
• Retained nuclear INI-1 expression in normal squamous epithelium and stromal fibroblasts.
• Complete loss of nuclear INI-1 expression in extrarenal malignant rhabdoid tumors of soft tissue.
• Complete loss of nuclear INI-1 expression in cribriform neuroepithelial tumors (CRINET).
• Retained nuclear INI-1 expression in choroid plexus papilloma and carcinoma.
• Retained nuclear INI-1 expression in ependymoma.
• Retained nuclear INI-1 expression in glioblastoma and astrocytoma.
• Retained nuclear INI-1 expression in melanoma and epithelioid angiosarcoma.
• Non-specific cytoplasmic staining with absent nuclear staining (interpreted as negative/loss of expression).
• Technical failure due to tissue under-fixation, resulting in weak or absent staining in both tumor and control cells.
• Technical failure due to prolonged decalcification of bone specimens, requiring repeat testing on alternative tissue blocks.
• Retained nuclear INI-1 expression in rhabdomyosarcoma.
• Retained nuclear INI-1 expression in epithelioid hemangioendothelioma.
• Equivocal nuclear staining in poorly preserved biopsies, indicating the need for molecular testing (SMARCB1 FISH or sequencing).

Turnaround Time and Report Access at Test Zone Diagnostic Center

At Test Zone Diagnostic Center in Lahore, Pakistan, we understand that a rapid and highly accurate diagnosis is critical for patients facing suspected malignancies. The turnaround time for specialized immunohistochemical tests like INI-1 typically ranges from 5 to 7 working days. This timeframe is necessary to ensure meticulous tissue processing, optimal antigen retrieval, precise staining protocols, and comprehensive microscopic evaluation by our consultant pathologists. Once the diagnostic report is finalized, patients and referring physicians are immediately notified via SMS. Reports can be accessed securely online through the Test Zone Diagnostic Center patient portal, allowing for rapid sharing with oncology teams. Physical copies of the reports can also be collected from our main diagnostic facility or designated collection centers across Lahore.

INI-1 Immunohistochemistry Findings Overview

Structure / Parameter Evaluated	Normal Findings	Possible Abnormal Findings
CNS Embryonal Tumors	Retained nuclear expression (e.g., Medulloblastoma)	Complete loss of nuclear expression (ATRT)
Epithelioid Soft Tissue Tumors	Retained nuclear expression (e.g., Synovial Sarcoma)	Complete loss of nuclear expression (Epithelioid Sarcoma)
Pediatric Renal Tumors	Retained nuclear expression (e.g., Wilms Tumor)	Complete loss of nuclear expression (Malignant Rhabdoid Tumor)
Adult Renal Tumors	Retained nuclear expression (e.g., Renal Cell Carcinoma)	Complete loss of nuclear expression (Renal Medullary Carcinoma)
Peripheral Nerve Sheath Tumors	Retained nuclear expression (e.g., Schwannoma)	Mosaic loss (Schwannomatosis) or complete loss (EMPNST)
Chordoma Subtypes	Retained nuclear expression (Classic Chordoma)	Complete loss of nuclear expression (Poorly Differentiated Chordoma)
Internal Positive Controls	Strong, diffuse nuclear expression in lymphocytes and endothelial cells	Absent expression in control cells (indicates technical staining failure)
Tissue Antigenicity	Preserved nuclear antigenicity with crisp staining	Weak or absent staining due to improper fixation or decalcification

Note: Diagnostic findings should always be interpreted by a qualified healthcare professional together with the patient’s symptoms, medical history, physical examination, laboratory investigations, previous imaging studies, and other relevant clinical information. Additional investigations or specialist consultation may be recommended depending on the findings.

Why Choose Test Zone Diagnostic Center for INI-1 Immunohistochemistry?

• Experienced healthcare professionals specializing in histopathology and oncological diagnostics.
• Patient-focused care ensuring a supportive and compassionate diagnostic journey.
• Quality diagnostic services utilizing automated immunohistochemistry staining platforms.
• Professional reporting with detailed microscopic descriptions and diagnostic interpretations.
• Modern diagnostic approach incorporating the latest evidence-based pathology guidelines.
• Comfortable environment at our main facility designed for patient convenience.
• Convenient location in Lahore, Pakistan, with multiple accessible collection centers.
• Commitment to accurate diagnosis to facilitate timely and effective clinical decision-making.